A Phase 1 interventional study of RPX7009 and Biapenem in Healthy Volunteers and Bacterial Infections, sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company). Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-11.
Sponsored by Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) (part of Novartis) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Bacterial Infections with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Bacterial Infections · Australia.
Among the 29 studies in Bacterial Infections with a site in Australia, this one is the 23rd largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2013, is one of 21 in phase 1, and was the 11th registered.
585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →1 of the 29 studies in Bacterial Infections with a site in Australia is open now. Recruiting first, the newest first:
Peter MacCallum Cancer Centre, Australia · Sites in Australia
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 84 across 383 interventional studies indexed under Bacterial Infections.
Median enrollment 65 across the 26 interventional studies, 790 across the 3 observational. Of the 26 that completed or were terminated, 3 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company), one of the names counted as Novartis. Under that name alone:
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) is the lead sponsor of 7 studies on the registry; none are open to participants now.
Novartis has 7 studies filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Bacterial Infections with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
RPX7009 (beta-lactamase inhibitor) is being studies in combination with a carbapenem biapenem to treat bacterial infections, including those due to multi-drug resistant bacteria.
The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections. In particular, the recent dissemination of a serine carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.
Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2003 or biapenem) plus a new beta-lactamase inhibitor (RPX7009) which has activity against serine beta-lactamases, including KPC. This Phase 1 study will assess the safety, tolerability and pharmacokinetics and pharmacodynamics of Intravenous Biapenem and RPX7009, administered alone and in combination in healthy adult subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single and multiple dose of normal saline
Drug: Normal saline
Single dose IV infusion of biapenem or RPX7009
Drug: RPX7009 · Drug: Biapenem
Single IV dose of biapenem or RPX7009 (for those on active drug, this will be the drug not given in the first IV treatment)
Drug: RPX7009 · Drug: Biapenem
Single dose followed by a multiple dose of biapenem and RPX7009 in combination
Drug: RPX7009 · Drug: Biapenem
Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Also known as: (beta-lactamase inhibitor)
Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Also known as: RPX2003
Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Also known as: Placebo
Safety from baseline to the end of the study
Number of patients with adverse events; assessed by patient reporting, collection of vital signs, ECGs and absolute values and changes over time of hematology, chemistry and urinalysis.
Time frame: Day 1 - Day 17
Composite of Pharmacokinetic (PK) parameters of RPX7009, biapenem & the combination following ascending single and multiple dose administration.
Comparison will be performed between the cohorts for the plasma AUC0-t, AUC0-inf, Cmax, and Tmax. Urine PK parameters such as amount excreted and % dose excreted will be calculated from urinary excretion data.
Time frame: Day 1 - Day 14
Composite of Pharmacodynamic (PD) parameters of RPX7009, biapenem & the combination following ascending single and multiple dose administration.
Serum for bactericidal titers (SBT) assessments will be collected on Days 1, 4, 7 and 14 (at the end-of-infusion (EOI)), and at 2, 4, and 8 hours after start of infusion.
Time frame: Days 1-14
The record gives a start of Mar 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: RPX7009
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) →